Deal covers multiple targets and gives Daiichi broad access to BioInvent’s antibody technologies.


BioInvent and Daiichi Sankyo signed a license and discovery agreement focused on developing therapeutic antibodies against multiple targets. The collaboration will see BioInvent work with Daiichi both in Japan and with the company’s German affiliate, U3 Pharma.

Under the terms of the agreement, Daiichi gains broad access to BioInvent’s discovery and development technology platform and in-house antibody expertise. Daiichi will fund all research work. BioInvent will earn an up-front access fee and annual maintenance fees for its antibody library plus success-based milestones. The company also will earn sales royalties but retains certain co-promotion rights in Scandinavia and the Baltic countries.

BioInvent’s in-house and partnered antibody discovery programs are based on its n-CoDeR® library. The company claims that the library contains over 20 billion highly diverse, fully human antibody fragments.

 








This site uses Akismet to reduce spam. Learn how your comment data is processed.